CRON Share Price | Cronos Group, Inc. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

279.22 k

Shareholding (Dec 2025)

FII

15.43%

Held by 335 FIIs

DII

84.18%

Held by 7 DIIs

Promoter

0.00%

Compare Cronos Group, Inc. with Similar Stocks

Jamieson Wellness, Inc.The Cannabist Company Holdings, Inc.Cipher Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared Positive results for the last 7 consecutive quarters

OPERATING CASH FLOW(Y) Highest at CAD 27.45 MM
OPERATING PROFIT MARGIN(Q) Highest at -1.06 %
RAW MATERIAL COST(Y) Fallen by -120.64% (YoY)

With ROE of 1.42%, it has a attractive valuation with a 0.92 Price to Book Value

Increasing Participation by Institutional Investors

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 1,346 Million (Small Cap)

P/E

165.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.76

Return on Equity

0.54%

Price to Book

0.90

Revenue and Profits:

Net Sales:

62 Million

(Quarterly Results - Dec 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-17.4%

6 Months

-8.92%

1 Year

27.17%

2 Years

10.86%

3 Years

25.75%

4 Years

-26.42%

5 Years

-72.47%

Cronos Group, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

26.83%

EBIT Growth (5y)

13.63%

EBIT to Interest (avg)

-152.00

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.78

Sales to Capital Employed (avg)

0.10

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.34%

ROCE (avg)

ROE (avg)

1.03%

Valuation key factors

Factor

Value

P/E Ratio

165

Industry P/E

Price to Book Value

0.90

EV to EBIT

-8.13

EV to EBITDA

-37.68

EV to Capital Employed

0.57

EV to Sales

1.01

PEG Ratio

Dividend Yield

ROCE (Latest)

-7.04%

ROE (Latest)

0.54%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 6 Schemes (0.38%)

Foreign Institutions

Held by 335 Foreign Institutions (15.43%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 24.20% vs 7.99% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -101.79% vs 173.17% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "62.10",
          "val2": "50.00",
          "chgp": "24.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-2.10",
          "chgp": "9.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.00",
          "val2": "-0.30",
          "chgp": "-2,900.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "39.00",
          "chgp": "-101.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-113.40%",
          "val2": "-138.30%",
          "chgp": "2.49%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 27.13% vs 36.87% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -107.48% vs 157.62% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "204.80",
          "val2": "161.10",
          "chgp": "27.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.60",
          "val2": "-67.40",
          "chgp": "93.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.30",
          "val2": "-7.70",
          "chgp": "5.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.10",
          "val2": "54.80",
          "chgp": "-107.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-119.60%",
          "val2": "-497.50%",
          "chgp": "37.79%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

62.10

50.00

24.20%

Operating Profit (PBDIT) excl Other Income

-1.90

-2.10

9.52%

Interest

0.00

Exceptional Items

-9.00

-0.30

-2,900.00%

Consolidate Net Profit

-0.70

39.00

-101.79%

Operating Profit Margin (Excl OI)

-113.40%

-138.30%

2.49%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 24.20% vs 7.99% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -101.79% vs 173.17% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

204.80

161.10

27.13%

Operating Profit (PBDIT) excl Other Income

-4.60

-67.40

93.18%

Interest

0.00

Exceptional Items

-7.30

-7.70

5.19%

Consolidate Net Profit

-4.10

54.80

-107.48%

Operating Profit Margin (Excl OI)

-119.60%

-497.50%

37.79%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 27.13% vs 36.87% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -107.48% vs 157.62% in Dec 2024

All Annual Results

Company CV

About Cronos Group, Inc.

Cronos Group, Inc.

Pharmaceuticals & Biotechnology

Cronos Group Inc is a cannabinoid company. The Company is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and Rest of World. The United States segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s subsidiaries include Cronos Israel G.S. Cultivations Ltd, Cronos Israel G.S. Manufacturing Ltd, Cronos Israel G.S. Store Ltd and Cronos Israel G.S. Pharmacies Ltd.

Company Coordinates

Company Details

Suite 300, 111 Peter Street , TORONTO ON : M5V 2G9

Tel: 1 416 5040004

https://thecronosgroup.com/

Registrar Details